iConcept Press Logo
Email Password Remember me
Cardiovascular Disease I
Title
Cardiovascular Disease I
Editor
iConcept Press
Price
USD$109.99
ISBN
978-1-922227-54-6
Clicks
37596

Chapter 11

Cardiovascular Disease I

Nanomedicine for the Diagnosis and Treatment of Cardiovascular Disease: Current Status and Future Perspective

by Evren Gundogdu, Zeynep Senyigit and Derya Ilem-Ozdemir

Viewed: 5138

Abstract

Cardiovascular disease (CVD) encompasses all pathologies of the heart or circulatory system, including coronary heart disease, peripheral vascular disease and stroke. Cardiovascular diseases are the primary morbidity and mortality cause in the world and seen among nearly 25% of adult population who are over 20 years of age, although it differs in continents and regions. The primary conditions underlying the great majority of cardiovascular diseases are dyslipidemia, atherosclerosis and hypertension. Treatments for CVD include non-invasive therapy such as prescription medication and lifestyle alterations, or surgical therapy such as coronary artery bypass grafting and angioplasty. Effective drug treatments for heart disease can help lower blood pressure or cholesterol, prevent or dissolve blood clots, relieve and prevent angina symptoms or improve the strength or rhythm of the heart's contractions. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, anti-clotting drugs and beta blokers are the examples of drug classes which are commonly used in CVD. Up to date, these drugs are mostly introduced into the market in conventional formulations such as tablets or capsules. During the past 20 years, with the detailed molecular level understanding of the diseases and the development of sophisticated technologies for nanoscale using, nanomedicine has undergone an explosive growth in the world. Nanomedicine is the application of nanotechnology in monitoring, diagnosing, preventing, repairing or curing diseases and damaged tissues in biological systems and it is gaining importance for the treatment of CVD. In the near future, it is considered that nanomedicine approach will enable establishment of patient-specific “personalized medicine”. It is also considered that gene therapies for cardiovascular applications will have a potential usage in the field of cardiovascular applications in upcoming years. This chapter focuses on recent formulations in cardiovascular therapy with comparison of conventional dosage forms. In addition, future perspectives for the treatment of CVD will be discussed in details.

Author Details

Evren Gundogdu
Radiopharmacy Department, Faculty of Pharmacy, Ege University, Turkey, Turkey
Zeynep Senyigit
Pharmaceutical Technology, Faculty of Pharmacy, Ege University, Turkey, Turkey
Derya Ilem-Ozdemir
Radiopharmacy, Faculty of Pharmacy, Ege University, Turkey, Turkey

Citation

Evren Gundogdu, Zeynep Senyigit and Derya Ilem-Ozdemir. Nanomedicine for the Diagnosis and Treatment of Cardiovascular Disease: Current Status and Future Perspective. In Cardiovascular Disease I. ISBN:978-1-922227-54-6. iConcept Press. 2014.

Download